• Longeveron Inc. Issues Special Equity Awards to Executive Chairman – SEC 8-K Filing Highlights Company Growth 7 Minichart Thu, 09 Jul 2026 00:59:00 GMT
• Form 4 Longeveron LLC For: 8 July By Investing.com Investing.com Nigeria Wed, 08 Jul 2026 23:03:32 GMT
• Longeveron (LGVN) CSO Hare granted 600k RSUs and 400k options Stock Titan Wed, 08 Jul 2026 22:00:29 GMT
• Longeveron grants special equity awards to Executive Chairman TipRanks Wed, 08 Jul 2026 20:46:00 GMT
• Longeveron (LGVN) awards 600,000 RSUs and 400,000 options to Executive Chairman Stock Titan Wed, 08 Jul 2026 20:06:27 GMT
• LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design Stocktwits Wed, 08 Jul 2026 18:57:25 GMT
• Form 4 Longeveron LLC For: 6 July By Investing.com Investing.com Nigeria Tue, 07 Jul 2026 01:36:49 GMT
• Longeveron (LGVN) CEO has 18,046 shares withheld to cover RSU tax obligations Stock Titan Tue, 07 Jul 2026 01:03:04 GMT
• Longeveron (NASDAQ: LGVN) CTO has 15,808 shares withheld for taxes Stock Titan Tue, 07 Jul 2026 01:03:04 GMT
• Longeveron (LGVN) CFO has shares withheld to cover RSU tax obligations Stock Titan Tue, 07 Jul 2026 01:03:03 GMT
• Longeveron (LGVN) counsel reports RSU tax-withholding share disposition Stock Titan Tue, 07 Jul 2026 01:03:02 GMT
• Longeveron (LGVN) CMO reports 22,505-share tax withholding after RSU vesting Stock Titan Tue, 07 Jul 2026 01:03:02 GMT
• Longeveron strengthens financial leadership with new CFO appointment TipRanks Mon, 06 Jul 2026 21:34:43 GMT
• Longeveron Appoints Marie Washburn as Chief Financial Officer citybiz Mon, 06 Jul 2026 20:43:35 GMT
• New Longeveron (NASDAQ: LGVN) CFO and reverse stock split approval Stock Titan Mon, 06 Jul 2026 20:31:34 GMT
• Longeveron® Appoints Marie Washburn as Chief Financial Officer GlobeNewswire Mon, 06 Jul 2026 20:05:00 GMT
• Press Release: Longeveron(R) Appoints Marie Washburn as Chief Financial Officer Moomoo Mon, 06 Jul 2026 20:05:00 GMT
• Longeveron taps Marie Washburn as CFO ahead of July trial readout Stock Titan Mon, 06 Jul 2026 20:05:00 GMT
• LGVN Q1 2026 Earnings: Wider Loss Misses Estimates as Pre-Revenue Biotech Faces Headwinds dars.gov.et Sun, 05 Jul 2026 18:38:16 GMT
• Enterprise value to EBITDA forward of Longeveron Inc. – NASDAQ:LGVN TradingView Tue, 30 Jun 2026 20:44:28 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design Stocktwits Mon, 29 Jun 2026 09:10:50 GMT
• longeveron® announces second quarter 2025 financial results and provides business update The National Law Review Mon, 29 Jun 2026 04:29:07 GMT
• Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update The National Law Review Sat, 27 Jun 2026 14:40:58 GMT
• lgvn shares rise after investigational therapy shows improvement in age-related frailty study Stocktwits Sat, 27 Jun 2026 12:28:25 GMT
• longeveron inc. class a actuals & estimates (nasdaq:lgvn) TradingView Fri, 26 Jun 2026 13:35:56 GMT
• longeveron inc (lgvn) earnings forecast: future eps & revenue growth estimates TradingKey Tue, 23 Jun 2026 07:00:00 GMT
• Longeveron to Present Additional Phase 2a Laromestrocel Data in Mild Alzheimer’s Disease at AAIC 2026 Quiver Quantitative Thu, 18 Jun 2026 07:00:00 GMT
• Longeveron gets AAIC poster slot for Alzheimer’s stem cell data Stock Titan Thu, 18 Jun 2026 07:00:00 GMT
• Longeveron’s Alzheimer’s trial data accepted for poster presentation Investing.com Thu, 18 Jun 2026 07:00:00 GMT
• New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentatio... Yahoo Finance Thu, 18 Jun 2026 07:00:00 GMT
• longeveron inc (lgvn) dividends & stock splits: historical payouts and event timeline TradingKey Wed, 17 Jun 2026 20:40:07 GMT
• longeveron inc (lgvn) risk assessment: volatility, financial risk & investment risk TradingKey Wed, 17 Jun 2026 13:49:39 GMT
• longeveron inc (lgvn) technical analysis: support, resistance, indicators & moving averages TradingKey Wed, 17 Jun 2026 11:38:57 GMT
• longeveron inc (lgvn) revenue breakdown: business segments, regional revenue & profit contribution TradingKey Wed, 17 Jun 2026 11:19:46 GMT
• longeveron inc (lgvn) financial health: profitability & balance sheet analysis TradingKey Wed, 17 Jun 2026 10:25:23 GMT
• longeveron inc (lgvn) shareholder structure: major shareholders & institutional holdings TradingKey Wed, 17 Jun 2026 10:24:27 GMT
• longeveron inc (lgvn) earnings forecast: future eps & revenue growth estimates TradingKey Wed, 17 Jun 2026 10:21:25 GMT
• longeveron inc (lgvn) valuation: pe, pb & fair value analysis TradingKey Wed, 17 Jun 2026 10:16:55 GMT
• longeveron inc (lgvn) technical analysis: support, resistance, indicators & moving averages TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• longeveron inc (lgvn) risk assessment: volatility, financial risk & investment risk TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• longeveron granted small or medium-sized enterprise (sme) status by the european medicines agency (ema) Yahoo Finance Tue, 09 Jun 2026 13:20:00 GMT
• Biotech Longeveron wins EMA SME status, where SME drugs saw 89% OKs Stock Titan Tue, 09 Jun 2026 07:00:00 GMT
• longeveron receives sme status from european regulator Investing.com Tue, 09 Jun 2026 07:00:00 GMT
• longeveron inc. awarded sme status by european medicines agency, enhancing drug development opportunities Quiver Quantitative Tue, 09 Jun 2026 07:00:00 GMT
• lgvn shares rise after investigational therapy shows improvement in age-related frailty study Stocktwits Mon, 08 Jun 2026 23:38:44 GMT
• lgvn q1 2026 earnings: deeper losses weigh on shares as clinical progress continues - gross profit margin newsline.com Sat, 06 Jun 2026 00:45:07 GMT
• longeveron - on june 1, lisa locklear to step down as cfo effective july 10, 2026 - sec filing TradingView Fri, 05 Jun 2026 20:35:28 GMT
• Longeveron (NASDAQ: LGVN) CFO Lisa Locklear to step down, controller eyed as successor Stock Titan Fri, 05 Jun 2026 07:00:00 GMT
• Longeveron to Present at BIO International Convention 2026 Taiwan News Thu, 04 Jun 2026 07:00:00 GMT
• stem cell firm longeveron seeks alzheimer’s, heart partners at bio 2026 Stock Titan Thu, 04 Jun 2026 07:00:00 GMT
• lgvn q1 2026 earnings: eps misses estimates as clinical-stage biotech continues r&d advances - capex guidance newsline.com Wed, 03 Jun 2026 07:00:00 GMT
• longeveron inc. (lgvn) extends decline: tests key support at $0.74 after 4.9% drop - dollar neutral pair newsline.com Fri, 29 May 2026 07:00:00 GMT
• longeveron inc. (lgvn) q1 2026 earnings: wider-than-expected loss pressures shares - profit announcement newsline.com Fri, 29 May 2026 07:00:00 GMT
• lgvn | longeveron inc. common stock executive compensation Quiver Quantitative Sun, 24 May 2026 10:48:28 GMT
• Longeveron Inc. Q1 2026 Earnings: EPS Misses Estimates Despite Stock Rally - Revenue Growth Report dars.gov.et Sun, 24 May 2026 07:00:00 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design MSN Sat, 23 May 2026 13:03:14 GMT
• longeveron ceo outlines strategy ahead of august trial data by investing.com Investing.com Nigeria Thu, 21 May 2026 07:18:27 GMT
• longeveron ceo outlines strategy focused on partnerships and 2026 milestones Investing.com India Thu, 21 May 2026 07:00:00 GMT
• longeveron anticipates august 2026 elpis ii readout while shifting to an asset-light partnering model MSN Wed, 20 May 2026 17:26:18 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design MSN Wed, 20 May 2026 17:11:22 GMT
• Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities Yahoo Finance Wed, 20 May 2026 07:00:00 GMT
• inside longeveron’s stem-cell push on a deadly infant heart defect Stock Titan Wed, 20 May 2026 07:00:00 GMT
• longeveron (nasdaq: lgvn) plans reverse split, bigger share pool and incentive plan Stock Titan Wed, 20 May 2026 07:00:00 GMT
• longeveron ceo outlines strategy ahead of august trial data by investing.com Investing.com Canada Wed, 20 May 2026 07:00:00 GMT
• Earnings call transcript: Longeveron Q1 2026 reveals strategic shift Investing.com Tue, 19 May 2026 07:00:00 GMT
• longeveron (lgvn) q1 2026 disappoints — eps $-0.19 below $-0.17 views - financial health score newsline.com Tue, 19 May 2026 07:00:00 GMT
• longeveron anticipates august 2026 elpis ii readout while shifting to an asset-light partnering model MSN Tue, 19 May 2026 01:51:22 GMT
• lgvn longeveron eps beats by 46 yet shares slip as investors seek revenue growth signals - tax rate impact newsline.com Sun, 17 May 2026 07:00:00 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design MSN Sun, 17 May 2026 04:18:12 GMT
• longeveron anticipates august 2026 elpis ii readout while shifting to an asset-light partnering model MSN Sat, 16 May 2026 11:46:57 GMT
• roth mkm maintains longeveron(lgvn.us) with buy rating, raises target price to $3 富途牛牛 Sat, 16 May 2026 04:12:34 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design MSN Fri, 15 May 2026 20:55:44 GMT
• longeveron anticipates august 2026 elpis ii readout while shifting to an asset-light partnering model MSN Fri, 15 May 2026 10:56:46 GMT
• analysts offer insights on healthcare companies: vtv therapeutics (vtvt), brookdale senior living (bkd) and longeveron (lgvn) The Globe and Mail Fri, 15 May 2026 07:00:00 GMT
• [schedule 13g] longeveron inc. passive investment disclosure (>5%) Stock Titan Fri, 15 May 2026 07:00:00 GMT
• longeveron earnings call: trial milestones amid fda hurdles The Globe and Mail Fri, 15 May 2026 07:00:00 GMT
• longeveron inc. (nasdaq:lgvn) q1 2026 earnings call transcript Insider Monkey Fri, 15 May 2026 07:00:00 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design MSN Thu, 14 May 2026 23:40:48 GMT
• longeveron inc. (lgvn) q1 2026 earnings call transcript summary Moomoo Thu, 14 May 2026 09:53:50 GMT
• longeveron anticipates august 2026 elpis ii readout while shifting to an asset-light partnering model MSN Thu, 14 May 2026 08:49:50 GMT
• Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update BioSpace Thu, 14 May 2026 07:00:00 GMT
• lgvn: q1 2026 featured stable revenue, lower expenses, and a pivotal hlhs trial readout expected in august TradingView Wed, 13 May 2026 22:53:01 GMT
• lgvn: cash runway extended into q4 2026 as focus shifts to key hlhs trial results and regulatory milestones TradingView Wed, 13 May 2026 22:19:46 GMT
• longeveron intends to seek additional financing opportunities, capital raises >lgvn Moomoo Wed, 13 May 2026 20:24:00 GMT
• longeveron announces 2026 first quarter financial results and provides business update GlobeNewswire Wed, 13 May 2026 07:00:00 GMT
• earnings call transcript: longeveron q1 2026 shows stability amid challenges Investing.com Wed, 13 May 2026 07:00:00 GMT
• stem cell trial for children’s rare heart defect set for august results Stock Titan Wed, 13 May 2026 07:00:00 GMT
• longeveron (nasdaq: lgvn) q1 2026 loss, cash jump and stem cell pipeline Stock Titan Wed, 13 May 2026 07:00:00 GMT
• longeveron (lgvn) boosts cash with financing but flags going-concern risk Stock Titan Wed, 13 May 2026 07:00:00 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design MSN Tue, 12 May 2026 01:44:42 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design Stocktwits Mon, 11 May 2026 10:45:30 GMT
• stem cell trial for children with rare heart defect passes final safety review Stock Titan Mon, 11 May 2026 07:00:00 GMT
• longeveron’s hlhs trial clears final safety review, data due august by investing.com Investing.com UK Mon, 11 May 2026 07:00:00 GMT
• longeveron's phase 2b trial for hlhs stem cell therapy gets positive safety review, continues to completion Pluang Mon, 11 May 2026 07:00:00 GMT
• longeveron reports dmc approval for laromestrocel study to continue as designed TipRanks Mon, 11 May 2026 07:00:00 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design MSN Sun, 10 May 2026 11:08:49 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design MSN Sat, 09 May 2026 21:57:34 GMT
• longeveron says the fda no longer sees trial for heart syndrome treatment as pivotal Moomoo Sat, 09 May 2026 20:11:32 GMT
• longeveron announces constructive type c meeting with u.s. fda ahead of data readout for elpis ii phase 2b clinical trial evaluati... The Manila Times Sat, 09 May 2026 07:00:00 GMT
• longeveron holds constructive fda type c meeting on elpis ii phase 2b trial for hlhs, top-line results expected august 2026 Minichart Sat, 09 May 2026 07:00:00 GMT
• longeveron faces setback as fda no longer views hlhs trial as pivotal Investing.com UK Sat, 09 May 2026 00:04:25 GMT
• rare heart syndrome trial loses pivotal label before august data Stock Titan Fri, 08 May 2026 20:07:55 GMT
• Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluati... Yahoo Finance Fri, 08 May 2026 07:00:00 GMT
• lgvn stock slips after hours as fda flags concerns on rare heart defect trial design Stocktwits Fri, 08 May 2026 07:00:00 GMT
• fda shifts stance on longeveron (lgvn) elpis ii hlhs trial but keeps future path open Stock Titan Fri, 08 May 2026 07:00:00 GMT
• longeveron faces setback as fda no longer views hlhs trial as pivotal Investing.com Canada Fri, 08 May 2026 07:00:00 GMT
• longeveron says the fda no longer sees trial for heart syndrome treatment as pivotal Moomoo Fri, 08 May 2026 07:00:00 GMT
• longeveron concludes fda meeting to discuss elpis ii phase 2b trial for hypoplastic left heart syndrome geneonline.com Fri, 08 May 2026 07:00:00 GMT
• longeveron provides update on laromestrocel development after type c meeting TipRanks Fri, 08 May 2026 07:00:00 GMT
• earnings preview: longeveron to report financial results post-market on may 13 Moomoo Fri, 08 May 2026 01:00:28 GMT
• h.c. wainwright maintains longeveron(lgvn.us) with buy rating, cuts target price to $8 富途牛牛 Wed, 06 May 2026 05:03:46 GMT
Longeveron Inc.(NASDAQ:LGVN) 
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cel...
Website: http://www.longeveron.com
Founded: 2014
CEO: Geoffrey Green
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends